The European Commission has announced plans to undertake a joint evaluation of the EU pediatric and orphan drugs legislation to determine why the combined effects of these legal instruments have failed to deliver major therapeutic advances in diseases that are rare and/or unique in children.
To support the evaluation, the commission has published a three-page roadmap explaining the content, purpose and scope of...







